Engineered immune cells take on tough T-Cell cancers

This early-stage trial tests whether a new type of CAR T-cell therapy is safe for children and adults with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target a protein called CCR9 on cancer cells. Participants receive a short course of chemotherapy before the infusion and are closely monitored in the hospital for at least two weeks.